Latest Articlesddd

NantKwest Inc: A Novel Breathtaking Immunotherapy for Cancer?

August 3, 2015 0

The moment the new IPO NantKwest (NK) landed in the town of publicly traded firms, some …

Prohost Letter #381

July 31, 2015 0

Prohost Letter #381 QUARTERLY FINANCIAL RESULTS IN THE BIOTECH SECTOR Investors Concerns, Excitement and Expectations (Part …

Prohost Letter #380

July 27, 2015 0

Prohost Letter #380 Investors Concerns, Excitments and Expectations PART 2  REGENERON On Friday, July 24, Regeneron …

Exelixis: The Importance of the Public Offering. Xoma: What Should We Do Now?

July 23, 2015 0

Why the financing through a secondary public offering was a must for Exelixis. The outcome of …

Amgen: Repatha Approved in Europe

July 21, 2015 0

The European Commission Approves Amgen’s New Cholesterol-Lowering Medication Repatha™ (evolocumab). The First PCSK9 Inhibitor to Be …

Anacor Pharmaceuticals Ointment for Atopic Dermatitis Passes the Tests. Why Is This Great News?

July 14, 2015 0

An Effective Non-Steroid Atopic Dermatitis Ointment Anacor Pharmaceuticals (ANAC) Announces Positive Top-Line Results From Two Phase …

Prohost Letter #379

July 12, 2015 0

Prohost Letter #379 Investors Concerns, Excitments and Expectations It is understandable the fact that bullish and …

TrovaGene: Overcoming Challenges in Cancer Immunotherapy

July 8, 2015 0

After decades of attempting, but failing, to harness the immune system power to treat cancer (Cancer …

Unearthing Dynavax Treasures Has Nothing to Do with Greece Troubles

June 29, 2015 0

Today it is Greece. What About Tomorrow? Can Greece’s crisis devastate the biotech sector? No sane …

Biocryst: A Major Game Changing Agreement

June 22, 2015 0

On Thursday June 18, 2015, we posted an article under “Today’s Highlights” at the Prohost website …

Prohost Letter #378 Part 2

June 9, 2015 0

Prohost Letter #378 Part 2 2015 ASCO ANNUAL MEETING What a Big Revolution in Oncology! The …

Immunogen: Defeating Advanced Ovarian Cancer and Other Malignancies

June 2, 2015 0

– Immunogen’s recurrent ovarian cancer drug Mirvetuximab soravtansine (IMGN853) has demonstrated promising results. – The firm …

A Company Report

May 29, 2015 0

VASCULAR BIOGENICS OPERATING AS VBL THERAPEUTICS Vascular Biogenics Ltd., operating as VBL Therapeutics (VBLT) is a …

Xoma: Phase 3 Eyeguard-B Trial Is Good News for Gevokizumab

May 27, 2015 0

Xoma (XOMA) announced good news from Phase 3 EYEGUARD-B trial of its monoclonal antibody drug gevokizumab …

Prohost Letter #378 Part 1

May 27, 2015 0

Prohost Letter #378 Part 1 Views and Visions TOP-TIER BIOTECHNOLOGY COMPANIES GILEAD We wrote a lot …

Immunotherapy at ASCO. What Do We Want to Hear?

May 22, 2015 0

For those who ask whether immunotherapy will have a dominant presence at ASCO, we confirm that …

Vertex: The FDA Advisory Committee Recommended Approval for Orkambi

May 13, 2015 0

AS WE AND PREDICTED, the FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC), voted in favor of approving …

The FDA Advisory Committee Voted in Favor of Amgen Melanoma Drug T-VEC and More Insight

April 29, 2015 0

The FDA Advisory Committee Voted 22-1 In Favor of Approval of Its Melanoma Immunotherapy T-VEC Yesterday’s …

Prohost Letter #377

April 21, 2015 0

Prohost Letter #377 PICKING BIOTECH FIRMS Before Investing in Them Raising the bar in designating small …

Celldex: Crossing the Border Towards a Higher Status

March 17, 2015 0

As you would observe when reading the most recent Prohost Letters, our recent enthusiasm for Celldex …